Volitionrx Historical Income Statement

VNRX Stock

USD 0.70 0.01 1.45%

Historical analysis of Volitionrx income statement accounts such as Interest Expense of 232.7 K, Other Operating Expenses of 38.6 M, Total Operating Expenses of 38.6 M or Total Other Income Expense Net of 326.2 K can show how well Volitionrx performed in making a profits. Evaluating Volitionrx income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Volitionrx's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Volitionrx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Volitionrx is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Volitionrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Volitionrx Stock please use our How to Invest in Volitionrx guide.

About Volitionrx Income Statement Analysis

Volitionrx Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Volitionrx shareholders. The income statement also shows Volitionrx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Volitionrx Income Statement Chart

At this time, Volitionrx's Interest Expense is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 38.6 M in 2024, despite the fact that Operating Income is likely to grow to (34.2 M).

Other Operating Expenses Ebitda Total Other Income Expense Net Selling General Administrative Research Development

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Volitionrx. It is also known as Volitionrx overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Volitionrx's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Volitionrx current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Volitionrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Volitionrx Stock please use our How to Invest in Volitionrx guide.At this time, Volitionrx's Interest Expense is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 38.6 M in 2024, despite the fact that Operating Income is likely to grow to (34.2 M).

	2021	2022	2023	2024 (projected)
Research Development	15.5M	14.6M	19.6M	10.0M
Depreciation And Amortization	1.1M	1.2M	1.4M	1.5M

Research Development Depreciation And Amortization

Volitionrx income statement Correlations

	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Net Income	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Income Tax Expense	Gross Profit	Cost Of Revenue	Selling General Administrative	Depreciation And Amortization	Research Development	Total Revenue	Net Income From Continuing Ops	Non Recurring	Interest Income	Net Interest Income	Selling And Marketing Expenses	Reconciled Depreciation	Minority Interest	Non Operating Income Net Other
Interest Expense		0.36	-0.35	-0.37	-0.34	-0.37	0.36	-0.35	0.34	-0.26	0.12	-0.33	0.34	0.29	0.32	0.24	-0.33	-0.46	-0.03	0.0	0.11	0.25	0.27	0.22
Other Operating Expenses	0.36		-0.99	-1.0	-1.0	-1.0	1.0	-0.99	0.55	-0.37	0.32	-0.23	0.96	0.96	0.88	0.78	-0.99	-0.68	-0.69	-0.1	0.44	0.9	0.88	0.8
Operating Income	-0.35	-0.99		1.0	1.0	1.0	-0.99	1.0	-0.58	0.38	-0.25	0.24	-0.95	-0.96	-0.92	-0.73	1.0	0.7	0.72	0.12	-0.47	-0.91	-0.86	-0.83
Ebit	-0.37	-1.0	1.0		0.99	1.0	-1.0	0.99	-0.6	0.42	-0.27	0.27	-0.95	-0.97	-0.91	-0.74	0.99	0.69	0.72	0.11	-0.46	-0.91	-0.86	-0.82
Net Income	-0.34	-1.0	1.0	0.99		0.99	-1.0	1.0	-0.53	0.33	-0.27	0.21	-0.95	-0.96	-0.91	-0.74	0.99	0.72	0.71	0.11	-0.46	-0.91	-0.86	-0.82
Ebitda	-0.37	-1.0	1.0	1.0	0.99		-1.0	0.99	-0.6	0.42	-0.27	0.27	-0.95	-0.96	-0.91	-0.74	0.99	0.69	0.72	0.11	-0.46	-0.9	-0.86	-0.82
Total Operating Expenses	0.36	1.0	-0.99	-1.0	-1.0	-1.0		-0.99	0.55	-0.37	0.32	-0.23	0.96	0.96	0.88	0.78	-0.99	-0.68	-0.69	-0.1	0.44	0.9	0.88	0.8
Income Before Tax	-0.35	-0.99	1.0	0.99	1.0	0.99	-0.99		-0.53	0.32	-0.27	0.22	-0.95	-0.96	-0.91	-0.74	0.99	0.73	0.71	0.11	-0.46	-0.9	-0.86	-0.82
Total Other Income Expense Net	0.34	0.55	-0.58	-0.6	-0.53	-0.6	0.55	-0.53		-0.85	-0.12	-0.65	0.51	0.57	0.59	0.21	-0.6	-0.25	-0.63	-0.22	0.47	0.56	0.43	0.6
Income Tax Expense	-0.26	-0.37	0.38	0.42	0.33	0.42	-0.37	0.32	-0.85		-0.07	0.71	-0.37	-0.4	-0.35	-0.25	0.4	0.03	0.45	-0.01	-0.14	-0.33	-0.28	-0.27
Gross Profit	0.12	0.32	-0.25	-0.27	-0.27	-0.27	0.32	-0.27	-0.12	-0.07		0.02	0.23	0.29	0.14	0.6	-0.23	-0.08	-0.07	-0.14	0.13	0.21	0.28	0.11
Cost Of Revenue	-0.33	-0.23	0.24	0.27	0.21	0.27	-0.23	0.22	-0.65	0.71	0.02		-0.21	-0.23	-0.26	-0.02	0.26	0.21	0.43	0.07	-0.08	-0.11	-0.07	-0.07
Selling General Administrative	0.34	0.96	-0.95	-0.95	-0.95	-0.95	0.96	-0.95	0.51	-0.37	0.23	-0.21		0.89	0.78	0.84	-0.96	-0.59	-0.57	0.01	0.31	0.84	0.94	0.76
Depreciation And Amortization	0.29	0.96	-0.96	-0.97	-0.96	-0.96	0.96	-0.96	0.57	-0.4	0.29	-0.23	0.89		0.89	0.72	-0.97	-0.63	-0.71	-0.03	0.47	0.94	0.81	0.82
Research Development	0.32	0.88	-0.92	-0.91	-0.91	-0.91	0.88	-0.91	0.59	-0.35	0.14	-0.26	0.78	0.89		0.5	-0.91	-0.73	-0.75	-0.16	0.47	0.89	0.65	0.85
Total Revenue	0.24	0.78	-0.73	-0.74	-0.74	-0.74	0.78	-0.74	0.21	-0.25	0.6	-0.02	0.84	0.72	0.5		-0.74	-0.26	-0.22	0.1	0.13	0.69	0.9	0.59
Net Income From Continuing Ops	-0.33	-0.99	1.0	0.99	0.99	0.99	-0.99	0.99	-0.6	0.4	-0.23	0.26	-0.96	-0.97	-0.91	-0.74		0.66	0.7	0.11	-0.47	-0.92	-0.88	-0.84
Non Recurring	-0.46	-0.68	0.7	0.69	0.72	0.69	-0.68	0.73	-0.25	0.03	-0.08	0.21	-0.59	-0.63	-0.73	-0.26	0.66		0.71	0.05	-0.27	-0.5	-0.37	-0.42
Interest Income	-0.03	-0.69	0.72	0.72	0.71	0.72	-0.69	0.71	-0.63	0.45	-0.07	0.43	-0.57	-0.71	-0.75	-0.22	0.7	0.71		0.22	-0.49	-0.57	-0.37	-0.52
Net Interest Income	0.0	-0.1	0.12	0.11	0.11	0.11	-0.1	0.11	-0.22	-0.01	-0.14	0.07	0.01	-0.03	-0.16	0.1	0.11	0.05	0.22		-0.72	-0.04	-0.04	-0.23
Selling And Marketing Expenses	0.11	0.44	-0.47	-0.46	-0.46	-0.46	0.44	-0.46	0.47	-0.14	0.13	-0.08	0.31	0.47	0.47	0.13	-0.47	-0.27	-0.49	-0.72		0.49	0.38	0.51
Reconciled Depreciation	0.25	0.9	-0.91	-0.91	-0.91	-0.9	0.9	-0.9	0.56	-0.33	0.21	-0.11	0.84	0.94	0.89	0.69	-0.92	-0.5	-0.57	-0.04	0.49		0.83	0.93
Minority Interest	0.27	0.88	-0.86	-0.86	-0.86	-0.86	0.88	-0.86	0.43	-0.28	0.28	-0.07	0.94	0.81	0.65	0.9	-0.88	-0.37	-0.37	-0.04	0.38	0.83		0.76
Non Operating Income Net Other	0.22	0.8	-0.83	-0.82	-0.82	-0.82	0.8	-0.82	0.6	-0.27	0.11	-0.07	0.76	0.82	0.85	0.59	-0.84	-0.42	-0.52	-0.23	0.51	0.93	0.76

Click cells to compare fundamentals

Volitionrx Account Relationship Matchups

Volitionrx income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	126.6K	129.8K	155.8K	173.1K	221.6K	232.7K
Other Operating Expenses	15.9M	20.6M	26.9M	30.9M	36.8M	38.6M
Operating Income	(16.0M)	(21.2M)	(28.3M)	(31.8M)	(36.0M)	(34.2M)
Ebit	(16.0M)	(20.3M)	(26.8M)	(30.4M)	(35.5M)	(33.7M)
Net Income	(16.0M)	(20.5M)	(27.0M)	(30.3M)	(35.3M)	(33.6M)
Ebitda	(15.1M)	(19.2M)	(25.7M)	(29.2M)	(34.0M)	(32.3M)
Total Operating Expenses	15.9M	20.6M	26.9M	30.9M	36.8M	38.6M
Income Before Tax	(16.1M)	(20.4M)	(27.0M)	(30.6M)	(35.7M)	(33.9M)
Total Other Income Expense Net	(56.1K)	848.5K	1.3M	1.2M	310.6K	326.2K
Income Tax Expense	(70.4K)	82.6K	(19.3K)	(329.7K)	(358.0K)	(340.1K)
Gross Profit	17.1K	13.4K	90.0K	(882.0K)	775.3K	814.1K
Selling General Administrative	4.5M	5.5M	8.6M	16.1M	15.9M	16.7M
Depreciation And Amortization	972.9K	1.0M	1.1M	1.2M	1.4M	1.5M
Research Development	10.4M	14.5M	15.5M	14.6M	19.6M	10.0M
Total Revenue	17.1K	13.4K	90.0K	306.4K	775.3K	814.1K
Net Income From Continuing Ops	(16.1M)	(20.4M)	(27.0M)	(31.8M)	(34.2M)	(32.5M)
Net Income Applicable To Common Shares	(16.1M)	(20.4M)	(26.8M)	(30.6M)	(27.5M)	(26.2M)
Interest Income	112.4K	49.5K	2.7K	125.3K	152.1K	87.7K
Net Interest Income	(14.2K)	(80.3K)	(153.1K)	(47.8K)	(68.7K)	(72.1K)
Selling And Marketing Expenses	965.7K	1.1M	4.1M	1.1M	1.0M	1.6M
Reconciled Depreciation	902.4K	1.0M	1.1M	1.2M	1.4M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Volitionrx Stock Analysis

When running Volitionrx's price analysis, check to measure Volitionrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Volitionrx is operating at the current time. Most of Volitionrx's value examination focuses on studying past and present price action to predict the probability of Volitionrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Volitionrx's price. Additionally, you may evaluate how the addition of Volitionrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Volitionrx Historical Income Statement

About Volitionrx Income Statement Analysis

Volitionrx Income Statement Chart

Other Operating Expenses

Volitionrx income statement Correlations

Volitionrx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Volitionrx income statement Accounts

Also Currently Popular

Additional Tools for Volitionrx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income From Continuing Ops	+ 1.0	Operating Income

Total Operating Expenses	- 1.0	Ebitda
Total Operating Expenses	- 1.0	Net Income
Total Operating Expenses	- 1.0	Ebit
Ebitda	- 1.0	Other Operating Expenses
Net Income	- 1.0	Other Operating Expenses
Ebit	- 1.0	Other Operating Expenses